← Back to headlines
Sanofi Unveils Phase 3 Amlitelimab Data for Atopic Dermatitis
Sanofi has announced late-breaking phase 3 data for its drug amlitelimab, targeting atopic dermatitis, a significant development in the treatment of the skin condition.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Ig Nobel Prizes Awarded at First Ceremony Held Outside the United States
8h ago
Dutch Soil Scientist Wins Ig Nobel Prize for Underwear Burial Experiment
15h ago
Quirky Research on Urinals and Candy Stealing Wins Ig Nobel Prizes
20h ago
WMO Predicts Record-Strength El Niño to Last Until February 2027
21h ago